Back to search results

Observational Study of MRI for Personalized Radiotherapy in High Grade Glioma

This study is looking at whether using repeated Magnetic Resonance Imaging (MRI) scans can help doctors adjust radiation treatment for people with high grade glioma (a type of brain tumor). Researchers want to see if these extra MRI scans can show changes in the tumor during treatment, which might lead to personalized adjustments in your radiation plan. You can join if you are at least 18 years old and have a confirmed diagnosis of high grade glioma. The study will look at how well the radiation covers the tumor and healthy tissues, and how this might affect your treatment outcomes over two years. This is an observational study with a planned enrollment of 80 participants, and its current status is unclear.

Study design
This is an observational study with a planned enrollment of 80 participants. It is not specified if it is randomized or blinded.
What's involved
You would undergo MRI scans, neurocognitive testing, quality-of-life assessments, and questionnaire administration.
Compensation
Not stated in the trial record.
Follow-up
The study will track differences in treatment and outcomes for up to 2 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT04771806

Serial Advanced Magnetic Resonance Imaging Scan for Guidance of Personalized Adaptive Radiotherapy for High Grade Glioma

Recruiting
Not specifiedAges 18+Observational
M.D. Anderson Cancer Center
~80 participants
Updated 2026-03-04 on ClinicalTrials.gov
What's tested:Magnetic Resonance ImagingNeurocognitive AssessmentQuality-of-Life AssessmentQuestionnaire Administration

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Differences in the delineated target and organ at risk volumes and dosimetry
Measured over Up to 2 years
+1 more outcome measured

Conditions

Malignant Glioma

Explore related trials

Glioma

Where it's being run

1 sites across 1 states
Texas1

Study leadership

  • Caroline Chung · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center

Who to contact

Caroline Chung
[email protected]
713-563-2300
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

All patients with histologic confirmation of high grade glioma
Patients must be age \>= 18 years
Patients must sign informed consent indicating that they are aware of the investigational nature of this study in keeping with the policies of the hospital. The only acceptable consent form is the one attached at the end of this protocol, and has been approved and amended by the MD Anderson Cancer Center (MDACC) Institutional Review Board (IRB)
Patients must have Karnofsky performance status (KPS) \>= 60
Patients must be able to obtain an MRI scan with gadolinium contrast
Female patients of childbearing age must not be pregnant as determined with a serum beta human chorionic gonadotropin (HCG) no greater than 14 days prior to study registration, or breastfeeding. (The exclusion is made because gadolinium may be teratogenic in pregnancy). Female patients who consent to participate in the study will need to use contraceptive methods for the duration of the study

What this trial measures

  • Differences in the delineated target and organ at risk volumes and dosimetryUp to 2 years

    Will be compared between the plans generated using the immediate post-op MRI versus (vs.) MR simulation. A Kolmogorov-Smirnov test will be used to assess distributional (histogram) changes between the two scenarios.

  • Cumulative dosimetric differences for the target volume and normal structuresUp to 2 years

    Cumulative dosimetric differences for the target volume and normal structures between an adaptive radiotherapy approach based on serial MR images vs. the conventionally delivered radiotherapy plan. A Kolmogorov-Smirnov test will be used to assess distributional (histogram) changes between the two scenarios.